252.20
price up icon1.01%   2.51
 
loading
Precedente Chiudi:
$249.69
Aprire:
$250.64
Volume 24 ore:
458.61K
Relative Volume:
0.44
Capitalizzazione di mercato:
$35.89B
Reddito:
$5.02B
Utile/perdita netta:
$1.31B
Rapporto P/E:
28.31
EPS:
8.91
Flusso di cassa netto:
$1.56B
1 W Prestazione:
+3.03%
1M Prestazione:
+4.24%
6M Prestazione:
+4.47%
1 anno Prestazione:
+19.21%
Intervallo 1D:
Value
$249.65
$252.48
Intervallo di 1 settimana:
Value
$239.94
$252.48
Portata 52W:
Value
$179.42
$263.05

Resmed Inc Stock (RMD) Company Profile

Name
Nome
Resmed Inc
Name
Telefono
(858) 746-2400
Name
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Name
Dipendente
9,980
Name
Cinguettio
@resmed
Name
Prossima data di guadagno
2024-10-24
Name
Ultimi documenti SEC
Name
RMD's Discussions on Twitter

Confronta RMD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Medical Instruments & Supplies icon
RMD
Resmed Inc
252.20 35.89B 5.02B 1.31B 1.56B 8.91
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
557.08 197.97B 8.71B 2.48B 1.75B 6.82
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
173.45 49.82B 20.87B 1.50B 2.59B 5.24
Medical Instruments & Supplies icon
ALC
Alcon Inc
87.79 42.51B 9.93B 1.12B 1.58B 2.25
Medical Instruments & Supplies icon
BAX
Baxter International Inc
30.26 15.65B 11.89B -560.00M 191.00M -1.10

Resmed Inc Stock (RMD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-19 Iniziato Morgan Stanley Overweight
2025-01-16 Iniziato Goldman Buy
2025-01-10 Iniziato Piper Sandler Neutral
2024-12-13 Iniziato Stifel Hold
2024-09-24 Iniziato Robert W. Baird Outperform
2024-09-18 Downgrade Wolfe Research Peer Perform → Underperform
2024-09-04 Downgrade Needham Buy → Hold
2024-06-25 Downgrade Oppenheimer Outperform → Perform
2024-06-24 Downgrade Citigroup Buy → Neutral
2024-02-06 Ripresa KeyBanc Capital Markets Overweight
2023-10-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-10-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Aggiornamento JP Morgan Neutral → Overweight
2023-09-29 Downgrade Wolfe Research Outperform → Peer Perform
2023-09-06 Aggiornamento Needham Hold → Buy
2023-09-05 Downgrade UBS Buy → Neutral
2023-08-01 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Iniziato UBS Buy
2023-04-14 Iniziato Mizuho Buy
2023-01-17 Aggiornamento JP Morgan Neutral → Overweight
2022-10-28 Downgrade Citigroup Buy → Neutral
2022-10-20 Aggiornamento BofA Securities Neutral → Buy
2022-10-12 Iniziato Jefferies Hold
2022-09-08 Aggiornamento Citigroup Neutral → Buy
2022-08-15 Downgrade CLSA Buy → Outperform
2022-08-12 Downgrade Citigroup Buy → Neutral
2022-08-12 Downgrade JP Morgan Overweight → Neutral
2022-08-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Iniziato Wolfe Research Outperform
2022-01-31 Aggiornamento Citigroup Neutral → Buy
2022-01-31 Aggiornamento Goldman Neutral → Buy
2022-01-28 Aggiornamento RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Aggiornamento BofA Securities Underperform → Neutral
2022-01-24 Aggiornamento JP Morgan Neutral → Overweight
2022-01-13 Aggiornamento CLSA Outperform → Buy
2022-01-13 Aggiornamento Robert W. Baird Neutral → Outperform
2021-12-21 Aggiornamento KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Aggiornamento Macquarie Neutral → Outperform
2021-10-22 Aggiornamento CLSA Underperform → Outperform
2021-08-02 Downgrade CLSA Outperform → Sell
2021-08-02 Downgrade Needham Buy → Hold
2021-07-28 Aggiornamento Jefferies Underperform → Hold
2021-07-26 Downgrade JP Morgan Overweight → Neutral
2021-07-14 Iniziato RBC Capital Mkts Underperform
2021-06-28 Downgrade Citigroup Buy → Neutral
2021-06-22 Aggiornamento Macquarie Neutral → Outperform
2021-06-22 Iniziato Robert W. Baird Neutral
2021-06-21 Reiterato Needham Buy
2021-06-16 Downgrade BofA Securities Neutral → Underperform
2021-06-09 Aggiornamento CLSA Sell → Outperform
2021-05-21 Aggiornamento JP Morgan Neutral → Overweight
2021-05-11 Aggiornamento Citigroup Neutral → Buy
2021-04-30 Downgrade Citigroup Buy → Neutral
2021-03-16 Aggiornamento Needham Hold → Buy
2020-11-02 Aggiornamento UBS Neutral → Buy
2020-10-30 Aggiornamento JP Morgan Underweight → Neutral
2020-10-27 Aggiornamento BofA Securities Underperform → Neutral
2020-08-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-06-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-05-01 Downgrade JP Morgan Neutral → Underweight
2020-05-01 Aggiornamento Oppenheimer Perform → Outperform
2020-02-18 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-02-03 Iniziato CLSA Underperform
2020-01-31 Downgrade UBS Buy → Neutral
2020-01-10 Iniziato Oppenheimer Perform
2019-11-22 Iniziato KeyBanc Capital Markets Sector Weight
2019-07-29 Aggiornamento UBS Neutral → Buy
2019-07-16 Downgrade UBS Buy → Neutral
2019-05-06 Aggiornamento UBS Neutral → Buy
2019-04-18 Aggiornamento JP Morgan Underweight → Neutral
2019-01-25 Downgrade Goldman Buy → Neutral
2019-01-25 Downgrade JP Morgan Neutral → Underweight
2018-10-26 Aggiornamento Credit Suisse Neutral → Outperform
2018-07-02 Iniziato Goldman Buy
Mostra tutto

Resmed Inc Borsa (RMD) Ultime notizie

pulisher
Jun 06, 2025

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

ResMed Inc Director Proposes Sale of Common Shares - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Successful Exits - University College Dublin

Jun 05, 2025
pulisher
Jun 04, 2025

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus

Jun 04, 2025
pulisher
Jun 03, 2025

ResMed CFO Sells Shares - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Resmed Inc Reports Decrease in CDI Issuance for May 2025 - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Resmed Inc Officer Plans Sale of Common Stock - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

ResMed’s global general counsel Michael Rider sells $9,994 in shares By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

ResMed’s global general counsel Michael Rider sells $9,994 in shares - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Dental Sleep Medicine Market Projected to Witness Massive GrowthResMed Inc., SomnoMed Limited - openPR.com

Jun 03, 2025
pulisher
Jun 02, 2025

Citi raises ResMed stock price target to AUD45 citing strong EPS growth - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Here's why I invested MORE money in ResMed shares last week - MSN

Jun 02, 2025
pulisher
May 30, 2025

There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st

May 30, 2025
pulisher
May 30, 2025

Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance

May 30, 2025
pulisher
May 29, 2025

ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks

May 29, 2025
pulisher
May 28, 2025

Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.

May 28, 2025
pulisher
May 27, 2025

ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks

May 27, 2025
pulisher
May 27, 2025

ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia

May 27, 2025
pulisher
May 24, 2025

ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com

May 24, 2025
pulisher
May 23, 2025

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Are Wall Street Analysts Bullish on ResMed Stock? - Inkl

May 23, 2025
pulisher
May 23, 2025

Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com

May 23, 2025
pulisher
May 23, 2025

Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN

May 22, 2025
pulisher
May 22, 2025

Down 5%: What's going on with the ResMed share price? - MSN

May 22, 2025
pulisher
May 21, 2025

RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire

May 21, 2025
pulisher
May 21, 2025

Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Should you buy the dip in the ResMed share price? - MSN

May 21, 2025
pulisher
May 20, 2025

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India

May 20, 2025
pulisher
May 20, 2025

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN

May 20, 2025
pulisher
May 20, 2025

Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com

May 15, 2025
pulisher
May 15, 2025

Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks

May 15, 2025
pulisher
May 15, 2025

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec

May 15, 2025
pulisher
May 15, 2025

Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance

May 15, 2025

Resmed Inc Azioni (RMD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
medical_instruments_supplies ALC
$87.79
price up icon 0.99%
medical_instruments_supplies BDX
$173.45
price up icon 1.41%
medical_instruments_supplies BAX
$30.26
price up icon 0.36%
medical_instruments_supplies WST
$224.69
price up icon 2.80%
$64.33
price up icon 2.00%
Capitalizzazione:     |  Volume (24 ore):